安必平收盘下跌2.66%，滚动市盈率1287.16倍，总市值28.80亿元

Core Viewpoint - Anbiping's stock closed at 30.78 yuan, down 2.66%, with a rolling PE ratio of 1287.16 times, significantly higher than the industry average of 59.32 times [1][2] Company Summary - Anbiping's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - The latest quarterly report for Q1 2025 shows a revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] Shareholder Information - As of March 31, 2025, Anbiping had 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - Anbiping ranks 122nd in the medical device industry based on PE ratio, with the industry median at 39.97 times and the average at 59.32 times [1][2]